Header Logo

Connection

Doris Benbrook to Rats

This is a "connection" page, showing publications Doris Benbrook has written about Rats.
Connection Strength

0.165
  1. Development of flexible-heteroarotinoids for kidney cancer. Mol Cancer Ther. 2009 May; 8(5):1227-38.
    View in: PubMed
    Score: 0.063
  2. Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2. PLoS One. 2018; 13(4):e0194046.
    View in: PubMed
    Score: 0.029
  3. Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs. Drug Chem Toxicol. 2013 Jul; 36(3):284-95.
    View in: PubMed
    Score: 0.020
  4. Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen. Mutat Res. 2012 Jul 04; 746(1):78-88.
    View in: PubMed
    Score: 0.019
  5. Metabolism of a sulfur-containing heteroarotionoid antitumor agent, SHetA2, using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008 Nov; 22(21):3371-81.
    View in: PubMed
    Score: 0.015
  6. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2. Cancer Chemother Pharmacol. 2006 Nov; 58(5):561-9.
    View in: PubMed
    Score: 0.013
  7. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol Cell Biol. 1994 Oct; 14(10):7025-35.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.